As recently as the end of May of this year, he had Merck as an "Outperform".
Here's this morning's news item covering it -- and a bit of it:
. . . .Other equities research analysts have also recently issued reports about the stock. Analysts at Jefferies Group downgraded shares of Merck & Co from a “buy” rating to a “hold” rating in a research note to investors on Friday. They now have a $50.00 price target on the stock, down previously from $53.00. Separately, analysts at Credit Suisse initiated coverage on shares of Merck & Co in a research note to investors on Tuesday, October 8th. They set a “neutral” rating and a $49.00 price target on the stock. Finally, analysts at TheStreet reiterated a “buy” rating on shares of Merck & Co in a research note to investors on Tuesday, October 8th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $51.09. . . .
Of course, we will -- as ever -- keep you apprised.
No comments:
Post a Comment